Study of A-319 in Patients With Relapsed or Refractory B-cell Lymphoma — A-319

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Relapsed or Refractory B-cell Lymphoma Clinical Trial

Official title:
A Phase I, Single Centre, Open-label, Dose-escalation Study of A-319 in Patients With Relapsed or Refractory B-cell Lymphoma

Status Not yet recruiting

Clinical Trial Summary

Title: A Phase I, Single Centre, Open-label, Dose-escalation Study of A-319 in Patients With Relapsed or Refractory B-cell Lymphoma

Protocol Number: SP071744 Study Stage: Phase I Study Number: 1 site Subject Number: up to 54 patients with Relapsed or Refractory B-cell Lymphoma ;

NCT number	NCT04056975
Study type	Interventional
Source	Generon (Shanghai) Corporation Ltd.
Contact	Yang Jing, Bachelor
Phone	8613524953174
Email	yangj@generonbiomed.com
Status	Not yet recruiting
Phase	Phase 1
Start date	September 15, 2019
Completion date	January 27, 2022

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06062641` - Selinexor Combined With R-GDP Regimen for TP53-altered R/R DLBCL	Phase 2
Recruiting	`NCT05806580` - Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma	Phase 4
Recruiting	`NCT03208556` - Safety and Efficacy of iPD1 CD19 eCAR T Cells in Relapsed or Refractory B-cell Lymphoma	Phase 1
Not yet recruiting	`NCT05814848` - A Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell Lymphoma	Phase 4
Recruiting	`NCT03391726` - CART-19 Cells for R/R B-cell Lymphoma	Phase 2/Phase 3
Recruiting	`NCT04887025` - Exploratory Study of a Novel Oncolytic Vaccinia Virus RGV004 in the Treatment of Refractory/Relapsed B-cell Lymphoma	Phase 1
Recruiting	`NCT05720052` - A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma	Phase 1/Phase 2
Recruiting	`NCT06045585` - JY231 Injection in the Treatment of Relapsed or Refractory B-cell Lymphoma	Early Phase 1